Selected Grantee Publications
The Splicing Factor hnRNPL Demonstrates Conserved Myocardial Regulation Across Species and Is Altered in Heart Failure
Draper et al., FEBS Letters. 2024.
https://pubmed.ncbi.nlm.nih.gov/39300280/
The 5-year mortality rate of heart failure (HF) is approximately 50%. Gene splicing, induced by splice factors, is a post-transcriptional modification of mRNA that may regulate pathological remodeling in HF. Researchers investigated the role of the splice factor heterogenous nuclear ribonucleoprotein-L (hnRNPL) in cardiomyopathy. hnRNPL protein expression is significantly increased in a male C57BL/6 transaortic constriction–induced HF mouse model and in clinical samples derived from canine or human HF patients. Cardiac-restricted knockdown of the hnRNPL homolog in Drosophila revealed systolic dysfunction and reduced life span. This study demonstrates a conserved cross-species role of hnRNPL in regulating heart function. Supported by ORIP (K01OD028205) and NHLBI.
Amphiphilic Shuttle Peptide Delivers Base Editor Ribonucleoprotein to Correct the CFTR R553X Mutation in Well-Differentiated Airway Epithelial Cells
Kulhankova et al., Nucleic Acids Research. 2024.
https://academic.oup.com/nar/article/52/19/11911/7771564?login=true
Effective translational delivery strategies for base editing applications in pulmonary diseases remain a challenge because of epithelial cells lining the intrapulmonary airways. The researchers demonstrated that the endosomal leakage domain (ELD) plays a crucial role in gene editing ribonucleoprotein (RNP) delivery activity. A novel shuttle peptide, S237, was created by flanking the ELD with poly glycine-serine stretches. Primary airway epithelia with the cystic fibrosis transmembrane conductance regulator (CFTR) R533X mutation demonstrated restored CFTR function when treated with S237-dependent ABE8e-Cas9-NG RNP. S237 outperformed the S10 shuttle peptide at Cas9 RNP delivery in vitro and in vivo using primary human bronchial epithelial cells and transgenic green fluorescent protein neonatal pigs. This study highlights the efficacy of S237 peptide–mediated RNP delivery and its potential as a therapeutic tool for the treatment of cystic fibrosis. Supported by ORIP (U42OD027090, U42OD026635), NCATS, NHGRI, NHLBI, NIAID, NIDDK, and NIGMS.
Cytomegalovirus Vaccine Vector-Induced Effector Memory CD4+ T cells Protect Cynomolgus Macaques From Lethal Aerosolized Heterologous Avian Influenza Challenge
Malouli et al., Nature Communications. 2024.
Development of a universal influenza vaccine that protects against seasonal strains and future pandemic influenza viruses is a necessity because of the limited efficacy of current influenza vaccines. Researchers developed a cynomolgus macaque β-herpesvirus cytomegalovirus (CyCMV) vaccine that targets the highly conserved proteins in influenza viruses. Male and female Mauritian-origin cynomolgus macaques (MCM) were vaccinated and boosted with the CyCMV vaccine prior to being challenged with small-particle aerosols containing highly pathogenic avian influenza (HPAI). MCMs receiving the CyCMV vaccine still presented with fever and pulmonary infiltration but demonstrated significant protection against HPAI-induced mortality. Unvaccinated MCMs challenged with HPAI did not survive. Survival was correlated with the magnitude of influenza-specific CD4+ T cells prior to infection. These results demonstrate the efficacy of a novel vaccine that protects against HPAI through a CD4 T cell–mediated response. Supported by ORIP (P51OD010425, P51OD011092) and NIAID.
Administration of Anti-HIV-1 Broadly Neutralizing Monoclonal Antibodies With Increased Affinity to Fcγ Receptors During Acute SHIV AD8-EO Infection
Dias et al., Nature Communications. 2024.
https://www.nature.com/articles/s41467-024-51848-y
Anti-HIV broadly neutralizing antibodies (bNAbs) mediate virus neutralization and antiviral effector functions through Fab and Fc domains, respectively. This study investigated the efficacy of wild-type (WT) bNAbs and modified bNAbs with enhanced affinity for Fcγ receptors (S239D/I332E/A330L [DEL]) after acute simian-HIVAD8-EO (SHIVAD8-EO) infection in male and female rhesus macaques. The emergence of the virus in the plasma and lymph nodes occurred earlier in macaques given DEL bNAbs than in those given WT bNAbs. Overall, the administration of DEL bNAbs revealed higher levels of immune responses. The results suggest that bNAbs with an enhanced Fcγ receptor affinity offer a potential therapeutic strategy by targeting HIV more effectively during early infection stages. Supported by ORIP (P40OD028116), NCI, and NIAID.
Comparison of the Immunogenicity of mRNA-Encoded and Protein HIV-1 Env-ferritin Nanoparticle Designs
Mu et al., Journal of Virology. 2024.
https://journals.asm.org/doi/10.1128/jvi.00137-24
Inducing broadly neutralizing antibodies (bNAbs) against HIV-1 remains a challenge because of immune system limitations. This study compared the immunogenicity of mRNA-encoded membrane-bound envelope (Env) gp160 to HIV-1 Env-ferritin nanoparticle (NP) technology in inducing anti-HIV-1 bNAbs. Membrane-bound mRNA encoding gp160 was more immunogenic than the Env-ferritin NP design in DH270 UCA KI mice, but at lower doses. These results suggest further analysis of mRNA design expression and low-dose immunogenicity studies are necessary for anti-HIV-1 bNAbs. Supported by ORIP (P40OD012217, U42OD021458) and NIAID.
Understanding Early HIV-1 Rebound Dynamics Following Antiretroviral Therapy Interruption: The Importance of Effector Cell Expansion
Phan et al., PLOS Pathogens. 2024.
https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1012236
Researchers developed dynamic models of virus–immune interactions, building on a prior theoretical framework, to investigate the dynamics of HIV-1 rebound following antiretroviral therapy (ART). These models were evaluated using viral load data from 24 patients (sex not specified) following ART interruption. Of these models, the best-performing model highlighted that individuals with a higher effector cell expansion rate maintain viral remission for extended periods post-ART. The findings indicate that effector cell expansion plays a critical role in viral rebound control. These results suggest the potential for viral dynamic models to predict and understand HIV-1 rebound after ART interruption, contributing to the development of targeted HIV treatment strategies. Supported by ORIP (R01OD011095) and NIAID.
Dual Blockade of IL-10 and PD-1 Leads to Control of SIV Viral Rebound Following Analytical Treatment Interruption
Pereira Ribeiro et al., Nature Immunology. 2024.
https://pubmed.ncbi.nlm.nih.gov/39266691
Pereira Ribeiro et al. tested a hypothesis that blockading two immune molecules, IL-10 and PD‑1, following treatment interruption could help control viral rebound in antiretroviral therapy (ART)–treated rhesus macaques infected with simian immunodeficiency virus (SIV), a nonhuman analogue of HIV. When measured at 24 weeks following treatment interruption, durable control of viral rebound was seen in 9 of 10 combo-treated macaques. The investigators also found that they could predict the control of viral rebound based on the induction of inflammatory cytokines, proliferation of effector CD8+ T cells, and reduced expression of BCL-2 in CD4+ T cells prior to treatment interruption. These results could provide a way to achieve long-lasting control of HIV infection after discontinuing ART. Supported by ORIP (U42OD011023, P51OD011132), NCI, and NIAID.
Sex-Specific Cardiac Remodeling in Aged Rats After Adolescent Chronic Stress: Associations with Endocrine and Metabolic Factors
Dearing et al., Biology of Sex Differences. 2024.
https://pubmed.ncbi.nlm.nih.gov/39180122
Cardiovascular disease is a leading cause of death in the world. The potential effects of chronic stress on the development and progression of cardiovascular disease in the aged heart are unknown. In this study, researchers investigated sex- and stress-specific effects on left ventricular hypertrophy (LVH) after aging. Male and female rats were exposed to chronic stress during adolescence and then challenged with a swim test and a glucose tolerance test before and after aging 15 months. As a group, female rats showed increased LVH in response to early life stress. Male rats showed individual differences in vulnerability. These results indicate that sex and stress history can interact to determine susceptibility to cardiovascular risks. Supported by ORIP (F30OD032120, T35OD015130) and NHLBI.
Immunization With Germ Line–Targeting SOSIP Trimers Elicits Broadly Neutralizing Antibody Precursors in Infant Macaques
Nelson et al., Science Immunology. 2024.
https://www.science.org/doi/10.1126/sciimmunol.adm7097
Broadly neutralizing antibodies (bnAbs) offer a promising approach for preventing and treating HIV infection, but the ability to induce bnAbs at protective levels has been a challenge. Previous studies have shown that children living with HIV develop bnAbs more efficiently than adults living with HIV. This study evaluated the ability of a stabilized form of Env—SOSIP—to elicit an immune response in young rhesus macaques. The SOSIP protein was engineered to activate naïve B cells expressing germline antibody precursors. Infant macaques were immunized with wild-type SOSIP (SOSIP) or germline-targeting SOSIP (GT1.1), followed by a SOSIP booster. Both SOSIP and GT1.1 induced a protective immune response, but only GT1.1 induced VRC01-like bnAb precursors—antibodies that bind Env’s CD4-binding site and provide the broadest possible protection. These results represent a possible childhood HIV immunization strategy that would elicit protective immunity before sexual debut. Supported by ORIP (P51OD011107), NCI, and NIAID.
Modeling Resistance to the Broadly Neutralizing Antibody PGT121 in People Living With HIV-1
Cassidy et al., PLOS Computational Biology. 2024.
https://pubmed.ncbi.nlm.nih.gov/38551976/
PGT121 is a broadly neutralizing antibody that demonstrated potent antiviral activity in an early clinical trial. Resistance to PGT121 monotherapy rapidly occurred in the majority of participants (sex unspecified), and the rebound viruses were entirely resistant to PGT121-mediated neutralization. However, two participants experienced long-term antiretroviral therapy–free viral suppression following antibody infusion and retained sensitivity to PGT121 upon viral rebound. Mathematical models showed the importance of the relative fitness difference between PGT121-sensitive and -resistant subpopulations prior to treatment. Researchers identified the treatment-induced competitive advantage of a resistant population as a primary driver of resistance and emphasized the high neutralization ability of PGT121 in both participants who exhibited long-term viral control. Supported by ORIP (R01OD011095) and NIAID.